期刊文献+

注射用培美曲塞二钠与0.9%氯化钠注射液及不同pH的5%葡萄糖注射液的配伍稳定性考察 被引量:1

Stability of Pemetrexed Disodium for Injection in 0.9% Sodium Chloride Injection or 5% Glucose Injection with Different pH
原文传递
导出
摘要 目的:考察注射用培美曲塞二钠与0.9%氯化钠注射液及不同pH的5%葡萄糖注射液在不同温度、光照条件下的配伍稳定性。方法:建立高效液相色谱法测定培美曲塞在不同配伍液中的含量;同时测定不同配伍液的pH、不溶性微粒,并检查外观。结果:培美曲塞二钠与0.9%氯化钠注射液或不同pH的5%葡萄糖注射液配伍后6 h内,配伍液的pH变化<2%,8 h内相对含量变化<2%;而8 h以上,不同放置条件下的配伍液出现pH变化>2%,相对含量变化>2%;所有条件下的不溶性微粒均符合《中国药典》(2010年版)规定。结论:注射用培美曲塞二钠于常温条件配伍后应在6 h内尽快完成临床输注。 OBJECTIVE: To observe the stability of Pemetrexed disodium for injection in 0.9% Sodium chloride injection or 5% Glucose injection with different pH under different temperatures and light conditions. METHODS: HPLC method was estab- lished to determine the contents of pemetrexed disodium in different mixtures; the pH, insoluble particles and appearance of the mixed infusions were detected. RESULTS: Within 6 hours, the variety of pH of pemetrexed disodium in 0.9% Sodium chloride in- jection or 5% Glucose injection with different pH was smaller than 2% ; within 8 hours, the variety of relative contents was also smaller than 2 % ; however, more than 8 hours, the changes mentioned above were larger than 2 % under different conditions. Un- der all conditions, insoluble particles were corresponding with the requirements of Chinese Pharmacopoeia (2010 edition). CON- CLUSIONS: Pemetrexed disodium for injection should be used up within 6 hours after compatibility under room temperature.
出处 《中国药房》 CAS CSCD 2014年第10期905-907,共3页 China Pharmacy
关键词 培美曲塞 配伍 稳定性 氯化钠注射液 葡萄糖注射液 Pemetrexed Compatibility Stability Sodium chloride injection Glucose injection
  • 相关文献

参考文献2

二级参考文献9

同被引文献24

  • 1纪春青.地塞米松磷酸钠注射液与盐酸昂丹司琼注射液存在配伍禁忌[J].中国药物经济学,2012(3):174.
  • 2Hesketh PJ. Chemotherapy-induced nausea and vomiting [J]. NEngl JMed, 2008,358(23) : 2 482.
  • 3Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexa- methasone versus granisetron plus dexamethasone for pre- vention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase Ⅲ trial[J]. Lancet Oncol, 2009,10(2):115.
  • 4Tricco AC, Soobiah C, Blondal E, et al. Comparative sa- fety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network me- ta-analysis[J]. BMC Med, 2015,18 (13) : 142.
  • 5National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology : antiemesis[EB/OL ]. [2015- 07-01].http ://www.nccn.org/professionals.
  • 6Gan T J, Diemunsch P, Habib AS, et al. Consensus guide- lines for the management of postoperative nausea and vomiting[J]. Anesth Analg, 2014,118 (1) : 85.
  • 7Longfield V. Compatibility and stability of 5-HT3 receptor antagonists: a pharmacology review[J]. Oncol Nuts Fo- rum, 2002,29(10) : 1 469.
  • 8Hagan RL, Mallett MS, Fox JL. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in in- fusion bags and syringes for 32 days[J]. Am J Health Syst Pharm, 1996,53(12) : 1 431.
  • 9Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in iv solutions and oral liquids and during simulated Y-site injection with selected drugs [J]. Am JHealth Syst Pharm, 1996,53 (3) : 294.
  • 10Pinguet F, Rouanet P, Martel P, et al. Compatibility and stability of granisetron, dexamethasone, and methylpred- nisolone in injectable solutions[J]. JPharm Sci, 1995,84 (2):267.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部